Clinical data of the patients in this study enrolled originally in two separate cohorts
| Cohort 1 (Möttönen) | Cohort 2 (Paimela et al) | |
|---|---|---|
| Patients (n) | 57 | 85 |
| Age, median (range) | 50 (17–79) | 46 (19–65) |
| Female/male, % | 68/32 | 80/20 |
| Disease duration at entry, months, median (range) | 7 (2–24) | 8 (2–12) |
| Rheumatoid factor found at entry, % | 58 | 67 |
| HLA-DR4 present, % | 56 | 64 |
| Mallya score at entry, median (range) | 2.7 (1.5–3.7) | 2.5 (1.3–3.6) |
| Larsen’s score at entry, median (range) | 0 (0–28) | 2 (0–22) |
| Followup period at the latest visit, months, median (range) | 91 (18–111) | 60 (36–84) |
| % Treated with SAARDs during the study | 100 | 100 |
| Maximum symptomatic time before the start of SAARD treatment, months | 24 | 12 |
| Patients with joint replacements during the study | 5 | 5 |